Arcutis Biotherapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Arcutis BiotherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -35.2% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 98% pro Jahr.

Wichtige Informationen

-35.2%

Wachstumsrate der Gewinne

35.9%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	98.0%
Eigenkapitalrendite	-96.7%
Netto-Marge	-204.4%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

Sep 26

Arcutis Biotherapeutics: A Name To Accumulate

Sep 18

Arcutis acquires privately-held biotech Ducentis BioTherapeutics

Sep 07

Aufschlüsselung der Einnahmen und Ausgaben

Wie Arcutis Biotherapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:ARQT Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	106	-217	197	98
31 Dec 23	60	-262	185	111
30 Sep 23	49	-268	173	121
30 Jun 23	11	-331	161	164
31 Mar 23	6	-327	143	177
31 Dec 22	4	-311	122	182
30 Sep 22	1	-311	104	201
30 Jun 22	0	-260	85	172
31 Mar 22	0	-235	69	165
31 Dec 21	0	-206	61	146
30 Sep 21	0	-169	49	120
30 Jun 21	0	-150	38	113
31 Mar 21	0	-144	32	134
31 Dec 20	0	-136	21	115
30 Sep 20	0	-114	17	99
30 Jun 20	0	-90	14	78
31 Mar 20	0	-63	9	34
31 Dec 19	0	-42	7	37
30 Sep 19	0	-35	5	31
30 Jun 19	0	-28	3	26
31 Mar 19	0	-23	2	21
31 Dec 18	0	-19	2	18

Qualität der Erträge: ARQT ist derzeit unrentabel.

Wachsende Gewinnspanne: ARQT ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ARQT ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 35.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ARQT verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: ARQT ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: ARQT hat eine negative Eigenkapitalrendite (-96.66%), da es derzeit unrentabel ist.

Arcutis Biotherapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Senior VP & Chief Medical Officer exercised options and sold US$201k worth of stock

Senior VP & Chief Medical Officer recently sold US$435k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Consensus revenue estimates increase by 36%

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology

President notifies of intention to sell stock

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023

Consensus revenue estimates increase by 26%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

New minor risk - Financial position

Price target decreased by 8.5% to US$41.71

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Announces Zoryve® (Roflumilast) Cream 0.3% Included in Preferred Position on National Formularies for CVS Caremark

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Price target decreased by 9.2% to US$45.50

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Director exercised options and sold US$104k worth of stock

Director exercised options and sold US$88k worth of stock

Director exercised options and sold US$130k worth of stock

Arcutis Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Director exercised options and sold US$102k worth of stock

Forecast to breakeven in 2025

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for ZORYVE Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

Arcutis Biotherapeutics, Inc. Enrolls First Patient in Phase 1B Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. Announces the Publication of Positive Patient-Reported Outcome Itch Data from Its Phase 2B Study Evaluating Once-Daily Roflumilast Cream (0.3% and 0.15%) in Adults with Chronic Plaque Psoriasis

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream

Consensus forecasts updated